

# ACQUISITION OPPORTUNITY: PROJECT NEXUS

## CUTTING-EDGE NEUROPSYCHIATRY TREATMENT FACILITY IN ILLINOIS

**20**  
Average Daily Census

**300+**  
Current Clients

**\$2.1M**  
2025 Revenue

**45%**  
EBITDA Margin

**Direct Care Model**  
In-Network as of April 2026

**Real Estate is Optional**

**Outpatient mental health,  
TMS/IV Ketamine, Psychiatry,  
Medication Management**

### Overview

- Provides treatment solutions for neuropsychiatric and neurological conditions in Illinois
- Illinois is grappling with escalating mental health issues, marked by a surge in adult cases and a critical shortage of healthcare providers to address the rising need
- The Company is a top private provider of rTMS treatments known for clinical innovation and exceptional patient outcomes through evidence-based integrative care
- Offers cutting-edge treatments such as TMS/Ketamine Combination Therapy, Hyperbaric Oxygen Therapy, Spravato (Esketamine) for depression, and Pathfinder Brain SPECT Imaging as part of a diverse range of service offerings
- Provides specialized interventions, especially for patients with prior unsuccessful treatments for conditions such as OCD, depression, anxiety, PTSD, schizophrenia, dementia, stroke, panic, ADHD, learning disability, etc.
- Daily clinical operations are guided by a specialized care model focused on advanced therapies for individuals with complex, treatment-resistant psychiatric and neurological disorders
- Offers advanced outpatient mental health and substance abuse care, acclaimed as a destination clinic with referrals spanning local, national, and global networks
- Pioneered the use of novel protocols, including a combination of Transcranial Magnetic Stimulation and IV ketamine
- Operates on fully direct care model, with patients covering costs up front, allowing the center to maintain pricing control, reduce administrative complexity, and deliver highly personalized care without the arbitrary limitations of insurance or government reimbursement systems
- Now In-Network with Blue Cross Blue Shield, Evernorth, Optum and Aetna as of April 2026.

### Financial Summary

|                        | Annualized 2025    |
|------------------------|--------------------|
| <b>Total Income</b>    | <b>\$2,160,278</b> |
| Total Expenses         | \$1,585,826        |
| Net Income             | \$574,452          |
| <b>Adjusted EBITDA</b> | <b>\$974,692</b>   |